

PAR Immunoassay NCI Publications

[Kinders, R. J., Hollingshead, M., Khin, S., Rubinstein, L., Tomaszewski, J.E., Doroshow, J.H., Parchment, R.E., and the National Cancer Institute Phase 0 Clinical Trials Team. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly \(ADP-Ribose\) Polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res. 2008 Nov; 14\(21\).](#)

[Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltout R, Simpson M, Tomaszewski JE, Doroshow JH. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv. 2007 Dec;7\(6\):325-34. Review. PMID: 18199854](#)

[Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rodriguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, Lin CT, Frost DJ, Luo Y, Giranda VL. An enzyme-linked immunosorbent poly\(ADP-ribose\) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem. 2008 Oct 15;381\(2\):240-7. Epub 2008 Jul 16. PMID: 18674509](#)